The safety profile of biologic therapies for juvenile idiopathic arthritis
Authors:
- Philip J. HashkesPHPhilip J. Hashkes
- Yosef UzielYUYosef Uziel
- Ronald M. LaxerRLRonald M. Laxer
- 31 August 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 6 (10) , 561-571
Abstract
The treatment of juvenile idiopathic arthritis (JIA) has been revolutionized by the use of novel biologic agents that have much improved patients' short-term and, according to early evidence, long-term outcomes. Currently available biologic agents used to treat patients with JIA include tumor necrosis factor (TNF) blockers, various agents that target interleukin (IL)-1 and the IL-6 receptor, T-cell co-stimulation inhibitors and antibodies to B-lymphocyte antigen CD20. These agents are increasingly used early in the course of the disease (often in combination with other immunosuppressive medications) and often for long periods of time, as patients can be difficult to wean from their use. Safety concerns (especially the long-term effects of biologic therapy) are, therefore, being examined more closely. For instance, in 2009, the FDA issued a warning related to the development of malignancies in patients with JIA who had used anti-TNF medications for >2.5 years. In this Review, data related to the safety profile of all currently available biologic agents used to treat JIA are examined, with a particular focus on anti-TNF therapy, the most studied biologic agent for JIA. Safety issues that need further study, including the implementation of registries to monitor long-term drug safety, are also discussed.Keywords
This publication has 64 references indexed in Scilit:
- Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extensionAnnals of the Rheumatic Diseases, 2010
- Mortality outcomes in pediatric rheumatology in the USArthritis & Rheumatism, 2010
- Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesAnnals of the Rheumatic Diseases, 2009
- High-dose Daclizumab for the Treatment of Juvenile Idiopathic Arthritis–Associated Active Anterior UveitisAmerican Journal of Ophthalmology, 2009
- Abatacept in difficult-to-treat juvenile idiopathic arthritisBiologics: Targets and Therapy, 2009
- Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter studyClinical Rheumatology, 2008
- Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patientsAnnals of the Rheumatic Diseases, 2008
- Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agentsThe Journal of Pediatrics, 2006
- Psoriasis after treatment of juvenile idiopathic arthritis with etanerceptAnnals of the Rheumatic Diseases, 2006
- Long‐term safety and efficacy of etanercept in children with polyarticular‐course juvenile rheumatoid arthritisArthritis & Rheumatism, 2006